Long-term follow-up of TScan TCR-T therapies
A Long-term Follow-up Study to Assess Safety in Participants Who Received an Investigational T-Cell Receptor Engineered T-Cell (TCR-T) Product
TScan Therapeutics, Inc. · NCT06976736
This follow-up will see if the TSC-100 and TSC-101 TCR-T therapies remain safe and continue to control disease over the long term in people who already received them.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years to 110 Years |
| Sex | All |
| Sponsor | TScan Therapeutics, Inc. (industry) |
| Locations | 2 sites (Duarte, California and 1 other locations) |
| Trial ID | NCT06976736 on ClinicalTrials.gov |
What this trial studies
Participants who previously received TSC-100 or TSC-101 in the TSCAN-001 protocol will be enrolled for long-term monitoring without receiving additional study drug. The study is observational and will collect safety and disease outcome data for 15 years from the date of original TCR-T administration. Participants may receive other clinically indicated cancer treatments while being followed. Routine visits and data collection will track late adverse events, durability of response, and survival outcomes.
Who should consider this trial
Good fit: Ideal candidates are people who previously received a TSC-100 or TSC-101 TCR-T product in a TScan-sponsored trial and can provide informed consent for long-term follow-up.
Not a fit: Patients who did not previously receive TSC-100 or TSC-101 or who are seeking a new investigational therapy are unlikely to receive direct treatment benefit from participating.
Why it matters
Potential benefit: If successful, the follow-up could show whether these TCR-T therapies have durable safety and long-lasting disease control, helping guide future patient care.
How similar studies have performed: Long-term follow-ups of other cellular therapies like CAR-T have provided valuable safety and durability data, but published long-term data specific to TScan's TCR-T products are limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants who received a TCR-T cellular therapy in a clinical study sponsored by TScan Therapeutics. * Signed informed consent. Exclusion Criteria: * None
Where this trial is running
Duarte, California and 1 other locations
- City of Hope — Duarte, California, United States (RECRUITING)
- Mount Sinai — New York, New York, United States (RECRUITING)
Study contacts
- Study coordinator: Madhavi Desai
- Email: medicalaffairs@tscan.com
- Phone: (857) 399-9832
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: AML, ALL, MDS, TSCAN, Cell Therapies, TCR-T Cell Therapy, Long Term Follow-Up, TSC-101